Azeria Therapeutics has picked up Syncona as an investor as it looks to bring its therapy for receptor-positive luminal breast cancer into the clinic.
Azeria Therapeutics, a UK-based oncology spinout of University of Cambridge and research charity Cancer Research UK (CRUK), yesterday received £32m ($41.2m) in a series B round led by commercialisation firm Syncona.
Syncona invested approximately $38m and was joined by CRT Pioneer Fund, the investment vehicle formed by CRUK’s tech transfer arm – Cancer Research Technology – that counts Syncona as its largest investor.
Founded in 2017, Azeria is advancing drug candidates for cancer based on pioneer factors that…